| Tara Wright, OTR/L | |
|
2940 E Banner Gateway Dr, Gilbert, AZ 85234-2168 | |
| (480) 813-7900 | |
| Not Available |
| Full Name | Tara Wright |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapy |
| Experience | 4 Years |
| Location | 2940 E Banner Gateway Dr, Gilbert, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447840244 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OTH-008337 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bhsm Rehabilitation Llc | 2062773138 | 1258 |
News Archive
After years studying the molecular bases of glioblastoma - the most common brain tumor and one of the most aggressive of all cancers, the group led by Dr. Joan Seoane , Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor has today published a study in Nature Medicine identifying USP15 as a critical protein in cancer which, thanks to its molecular characteristics, shows enormous therapeutic promise.
Research published today by psychologists at the University of Bath suggests that 'Spice' – which contains synthetic drugs originally designed to mimic the effects of cannabis – is more harmful than cannabis and that users are likely to experience more severe withdrawal symptoms when attempting to quit.
Black men are three times more likely to develop prostate cancer than other demographics, yet black men are consistently underrepresented in research studies, say researchers from King's College London in a new paper published in ecancermedicalscience.
Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.
HMS Holdings Corp. (NASDAQ:HMSY) today announced it will report its third quarter 2013 financial and operating results at 8:00 a.m. Central/9:00 a.m. Eastern on Friday, November 8, 2013. Supplemental financial information including the press release and presentation will be available at http://investor.hms.com/events.cfm at approximately 7:30 a.m. Eastern on November 8.
› Verified 9 days ago
| Provider Name | Bhsm Rehabilitation Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1497271431 PECOS PAC ID: 2062773138 Enrollment ID: O20180306002185 |
News Archive
After years studying the molecular bases of glioblastoma - the most common brain tumor and one of the most aggressive of all cancers, the group led by Dr. Joan Seoane , Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor has today published a study in Nature Medicine identifying USP15 as a critical protein in cancer which, thanks to its molecular characteristics, shows enormous therapeutic promise.
Research published today by psychologists at the University of Bath suggests that 'Spice' – which contains synthetic drugs originally designed to mimic the effects of cannabis – is more harmful than cannabis and that users are likely to experience more severe withdrawal symptoms when attempting to quit.
Black men are three times more likely to develop prostate cancer than other demographics, yet black men are consistently underrepresented in research studies, say researchers from King's College London in a new paper published in ecancermedicalscience.
Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.
HMS Holdings Corp. (NASDAQ:HMSY) today announced it will report its third quarter 2013 financial and operating results at 8:00 a.m. Central/9:00 a.m. Eastern on Friday, November 8, 2013. Supplemental financial information including the press release and presentation will be available at http://investor.hms.com/events.cfm at approximately 7:30 a.m. Eastern on November 8.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tara Wright, OTR/L 2403 W Dusty Wren Dr, Phoenix, AZ 85085-7034 Ph: (602) 410-8006 | Tara Wright, OTR/L 2940 E Banner Gateway Dr, Gilbert, AZ 85234-2168 Ph: (480) 813-7900 |
News Archive
After years studying the molecular bases of glioblastoma - the most common brain tumor and one of the most aggressive of all cancers, the group led by Dr. Joan Seoane , Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor has today published a study in Nature Medicine identifying USP15 as a critical protein in cancer which, thanks to its molecular characteristics, shows enormous therapeutic promise.
Research published today by psychologists at the University of Bath suggests that 'Spice' – which contains synthetic drugs originally designed to mimic the effects of cannabis – is more harmful than cannabis and that users are likely to experience more severe withdrawal symptoms when attempting to quit.
Black men are three times more likely to develop prostate cancer than other demographics, yet black men are consistently underrepresented in research studies, say researchers from King's College London in a new paper published in ecancermedicalscience.
Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.
HMS Holdings Corp. (NASDAQ:HMSY) today announced it will report its third quarter 2013 financial and operating results at 8:00 a.m. Central/9:00 a.m. Eastern on Friday, November 8, 2013. Supplemental financial information including the press release and presentation will be available at http://investor.hms.com/events.cfm at approximately 7:30 a.m. Eastern on November 8.
› Verified 9 days ago
Mrs. Dana Sue Simpson, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 140 S Gilbert Rd, Gilbert, AZ 85296 Phone: 480-558-5131 Fax: 480-507-1616 | |
Mr. Giovanni Priano, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 2940 E Banner Gateway Dr, Ste. 200, Gilbert, AZ 85234 Phone: 480-964-2908 Fax: 480-833-2136 | |
Iman Lee Johnson, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1000 E Mesquite St, Gilbert, AZ 85296 Phone: 480-668-1917 Fax: 480-668-2750 | |
Mrs. Kristine Ann Smith, OT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 4902 S Val Vista Dr, Suite B102, Gilbert, AZ 85298 Phone: 480-855-8866 Fax: 480-855-8867 | |
Kristin Marie Anderson, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 140 S Gilbert Rd, Gilbert, AZ 85296 Phone: 480-497-3300 | |
Lauren Elizabeth Janke, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 690 E Warner Rd Ste 105, Gilbert, AZ 85296 Phone: 480-820-6366 | |
Sadie Elise Anderson, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 854 E Williams Field Rd Ste 105, Gilbert, AZ 85295 Phone: 480-398-4280 Fax: 844-526-2649 |